Metastatic Soft Tissue Sarcoma Clinical Trial
Official title:
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Verified date | September 2013 |
Source | ImmunityBio, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 2b, randomized, open-label, prospective, multicenter study comparing treatment with INNO 206 to doxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy except potentially as adjuvant or neoadjuvant chemotherapy, and no evidence of tumor recurrence has occurred for at least 12 months.
Status | Completed |
Enrollment | 126 |
Est. completion date | December 15, 2014 |
Est. primary completion date | April 9, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 80 Years |
Eligibility | Inclusion Criteria: - Age between 15-80 years (US only), and 18-80 (rest of world (ROW)), male or female. - Adjuvant or neoadjuvant chemotherapy (including doxorubicin) allowed if no tumor recurrence for at least 12 months since the last measurement, beginning or end of last chemotherapy. - Histologically or cytologically confirmed, locally advanced, unresectable, and/or metastatic soft tissue sarcoma of intermediate or high grade. - Capable of providing informed consent and complying with trial procedures. - ECOG performance status 0-2. - Life expectancy > 12 weeks. - Measurable tumor lesions according to RECIST 1.1 criteria. - Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. (Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.) - Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. - Geographic accessibility to the site that ensures the subject will be able to keep all study-related appointments. Exclusion Criteria: - Prior chemotherapy unless for adjuvant or neoadjuvant therapy with no tumor recurrence for at least 12 months. - Prior exposure to > 3 cycles or 225 mg/m2 of doxorubicin or Doxil®. - Palliative surgery and/or radiation treatment less than 4 weeks prior to Randomization. - Exposure to any investigational agent within 30 days of Randomization. - Current Stage 1 or 2 soft tissue sarcomas. - Current evidence/diagnosis of alveolar soft part sarcoma, chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST), dermatofibrosarcoma, Ewing's sarcoma, Kaposi's sarcoma, mixed mesodermal tumor, clear cell sarcomas and unresectable low grade liposarcomas. - Central nervous system metastasis - History of other malignancies except cured basal cell carcinoma, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for > 5 years. - Laboratory values: Screening serum creatinine > 1.5x upper limit of normal (ULN), alanine aminotransferase (ALT) > 3 × ULN or >5 × ULN if liver metastases are present, total bilirubin > 3 × ULN, absolute neutrophil count < 1,500/mm3, platelet concentration < 100,000/mm3, hematocrit level < 25% for females or < 27% for males, or coagulation tests (prothrombin time [PT], partial thromboplastin time [PTT], International Normalized Ratio [INR]) > 1.5 × ULN, albumin < 2.0 g/dL. - Clinically evident congestive heart failure > class II of the New York Heart Association (NYHA) guidelines. - Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V. - Baseline QTc > 470 msec and/or previous history of QT prolongation while taking other medications. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed. - History or signs of active coronary artery disease with or without angina pectoris. - Serious myocardial dysfunction defined as scintigraphically (e.g. MUGA, myocardial scintigram) or ultrasound determined absolute left ventricular ejection fraction (LVEF) < 45% of predicted. - History of HIV infection. - Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals. - Major surgery within 3 weeks prior to Randomization. - Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results. - Any condition that is unstable and could jeopardize the subject's participation in the study. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Hobart Hospital | Hobart | |
Australia | Mount Medical Centre | Perth | |
Australia | Royal Perth Hospital | Perth | |
Australia | Epworth HealthCare Clinical Trials and Research Centre | Richmond | Victoria |
Australia | Royal North Shore | St. Leonards | New South Wales |
Australia | The Crown Princess Mary Cancer Centre Westmead | Sydney | |
Australia | Border Medical Oncology | Wodonga | Victoria |
Hungary | State Health Centre Oncology Department | Budapest | |
India | Hemato Oncology Clinic, Vedanta Institute of Medical Science | Ahmedabad | Gujarat |
India | M.S. Ramaiah Medical College and Hospitals | Bangalore | Karnataka |
India | Noble Hospital Clinical Research Department 1st Floor | Hadapsar | Pune Maharashtra |
India | Delhi State Cancer Institute | Mandoli | Delhi |
India | Tata Memorial Hospital, Department of Medical Oncology | Mumbai | |
India | Curie Manavata Cancer Centre | Nashik | Maharashtra |
India | Delhi State Cancer Institute | Pune | Maharashtra |
India | Jehangir Clinical Development Centre Pvt Ltd | Pune | Maharashtra |
India | Hemato Oncology Clinic, Vedanta Institute of Medical Science | Thaltej | Ahmedaba |
India | Christian Medical College | Vellore | Tami Nadu |
Romania | Spitalul Judetean de Urgenta "Dr. Constantin Opris" Baia-Mare, Sectia Oncologie | Baia-Mare | Judet Maramures |
Romania | Medisprof SRL | Cluj-Napoca | |
Romania | Oncological Institute "Prof. Dr. I. Chiricuta", Cluj-Napoca | Cluj-Napoca | County Cluj |
Romania | Clinical County Hospital Mures, Medical Oncology Department | Targu-Mures | County Mures |
Russian Federation | State Healthcare Institution "Republican Clinical Oncological Center of the Ministry of Health of Republic of Tatarstan" | Kazan | Republic Of Tatarstan |
Russian Federation | Blokhin Cancer Research Center | Moscow | |
Ukraine | Municipal institution "Chernivtsi Regional Clinical Oncologic Dispensary", | Chernivtsi | |
Ukraine | Municipal Institution "Dnipropetrovsk City Multi-Field Clinical Hospital #4" of Dnipropetrovsk Regional Councel | Dnipropetrovsk | |
Ukraine | State Institution "Institute of Medical Radiology named after S.P.Grygoryev of National Academy of Medical Sciences of Ukraine", | Kharkiv | |
Ukraine | Lviv State Oncological Regional Treatment - Diagnostics Center, Chemotherapy Department | Lviv | |
Ukraine | Vinnytsya Regional Clinical Oncologic Dispensary, Surgical Department | Vinnytsya | |
United States | University of Iowa | Iowa City | Iowa |
United States | Pennsylvania Hematology Oncology Associates | Philadelphia | Pennsylvania |
United States | CTRC Institute for Drug Development, University of Texas | San Antonio | Texas |
United States | Sarcoma Oncology Center | Santa Monica | California |
United States | Stanford University | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
ImmunityBio, Inc. |
United States, Australia, Hungary, India, Romania, Russian Federation, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival | Progression-free survival is defined as the interval from the date of registration (ie, assignment of subject number) to the earliest date of documented evidence of recurrent or progressive disease, or the date of death due to any cause, whichever occurs first.
Progressive Disease is defined as: 20% increase in the sum of the longest diameter of target lesions from the smallest sum of the longest diameter recorded since the treatment started; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 new lesion is also considered progression. |
Approximately 24 months | |
Secondary | Overall Survival | Overall survival was measured from the date of registration (ie, assignment of subject number) to the date of death due to any cause, or the date of last contact. | Approximately 35 months | |
Secondary | Progression-free Survival at 4 and 6 Months | Month 4 and 6 | ||
Secondary | Objective Overall Response Rate (ORR) | Objective Overall Response will be evaluated using the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1). Changes (i.e., improvements) in tumor measurements from baseline values will be assigned a status of CR or PR. Objective response measurements will comprise the sum of CR plus PR.
Complete Response (CR): disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm). Partial Response (PR): 30% decrease in the sum of the longest diameter of target lesions, from the baseline sum longest diameter. |
Approximately 24 months | |
Secondary | Number of Participants With Treatment-related Toxicities (Adverse Events) | Treatment will continue every 21 days until tumor progression is observed, 6 cycles of treatment are completed or unacceptable toxicity occurs. | 30 days after last dose, up to 136 days (6 cycles of treatment plus 30 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03670069 -
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
|
Phase 1 | |
Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03793361 -
Phase II Study of Regorafenib as Maintenance Therapy
|
Phase 2 | |
Completed |
NCT03009201 -
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
|
Phase 1 | |
Withdrawn |
NCT03397186 -
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
|
Phase 2 | |
Recruiting |
NCT03965234 -
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT04028063 -
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT04200443 -
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT05711615 -
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
|
Phase 1 | |
Completed |
NCT01574716 -
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
|
Phase 2 | |
Completed |
NCT02500797 -
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT03138161 -
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03660930 -
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
|
Phase 1/Phase 2 |